Commercialisation Australia (CA) is now closed for new applications, following the announcement in last week's federal Budget that it will cease from 1 January 2015 and the funds will be rolled into the new Entrepreneurs' Infrastructure Program (EIP). [ + ]

Immune System Therapeutics (IST) has announced plans to place up to $5m in new shares, to raise funds for a phase IIb multiple myeloma trial and an ASX listing in the third quarter. [ + ]

A comprehensive systematic review of childhood vaccinations has found no evidence of a link to the development of autism or autism spectrum disorders. [ + ]

Entries are open for this year's The Australian Innovation Challenge awards, honouring excellence in fields from minerals and energy to ICT and community services. [ + ]

Lou Panaccio, an executive with more than 30 years of healthcare and life science experience, has joined the board of Avita Medical (ASX:AVH) as its chairman. [ + ]

Positive results in initial trails suggest gene therapy could treat a common cause of blindness. [ + ]

The Research Australia Awards 2014 are calling for nominations of those making an impact early in their research career; those constantly advocating for health and medical research; philanthropic heroes; and exceptional leaders and pioneers. [ + ]

As part of World Metrology Day, Parliamentary Secretary for Industry Bob Baldwin has announced the winners of this year's National Measurement Institute (NMI) awards. [ + ]

The federal government's first Budget delivers a mixed outcome for science, research and innovation. [ + ]

GI Dynamics (ASX:GID) said Australian type 2 diabetes patients treated with its EndoBarrier therapy were able to reduce or eliminate insulin therapy. [ + ]

If you are a professional working in the therapeutics sector, don't miss the 2014 ARCS Scientific Congress to be held in Sydney at the beginning of June. [ + ]

QUT and Wollongong University, along with two European Institutes, are the first to offer a course in biofabrication. [ + ]

The biotech sector is regrouping after the bruising Federal Budget on Tuesday night delivered a round of cuts for biotechnology, including measures to reduce the R&D Tax Incentive and abolish the Innovation Investment Fund (IIF) and Commercialisation Australia (CA). [ + ]

Clinuvel Pharmaceuticals (ASX:CUV) has closed a $7.2m private placement, to help fund development of Scenesse in vitiligo and a post-marketing study of the drug in EPP. [ + ]

Neurodegenerative disease expert professor Ira Shoulson has joined the Prana Biotechnology (ASX:PBT) board to help the company develop PBT2 as a treatment for Huntington disease. [ + ]